Carregant...
Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms
PURPOSE: Netarsudil is a Rho kinase/norepinephrine transporter inhibitor currently in phase 3 clinical development for glaucoma treatment. We investigated the effects of its active metabolite, netarsudil-M1, on outflow facility (C), outflow hydrodynamics, and morphology of the conventional outflow p...
Guardat en:
| Publicat a: | Invest Ophthalmol Vis Sci |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
The Association for Research in Vision and Ophthalmology
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5114035/ https://ncbi.nlm.nih.gov/pubmed/27842161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1167/iovs.16-20189 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|